VT
MDGL icon

Vise Technologies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vise Technologies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
834
+65
+8% +$33.3K 0.01% 1224
2026
Q1 		$448K Hold
769
– – 0.01% 927
2025
Q4 		$448K Buy
+769
New +$393K 0.01% 933

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vise Technologies's MDGL Position: Q2 2026 in Review

Vise Technologies increased its Madrigal Pharmaceuticals (MDGL) stake by 8.5% in Q2 2026, buying an estimated $33.3K and bringing the position to 834 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #1224.

Vise Technologies first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $448K in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Vise Technologies held 834 shares of Madrigal Pharmaceuticals worth $448K as of Q2 2026.
  • Vise Technologies bought 65 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $33.3K.
  • Madrigal Pharmaceuticals made up 0.01% of Vise Technologies's portfolio in Q2 2026, its #1224 holding.
  • Vise Technologies first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Vise Technologies's Madrigal Pharmaceuticals position peaked at $448K in Q1 2026.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.